Schroder Investment Management Group
ANIP icon

Schroder Investment Management Group’s ANI Pharmaceuticals ANIP Stock Holding History

Schroder Investment Management Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,857
Closed -$734K – 1158
2025
Q1 		$734K Buy
+10,857
New +$648K ﹤0.01% 1039

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Schroder Investment Management Group's ANIP Position: Q2 2025 in Review

Schroder Investment Management Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2025, closing a stake of 10,857 shares — an estimated $734K sold.

Schroder Investment Management Group first reported a position in ANIP in Q1 2025 and held it in 1 quarter. The position peaked at $734K in Q1 2025. 232 funds tracked by Wall St. Rank hold ANIP as of Q2 2025.

  • Schroder Investment Management Group reported no remaining ANI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 10,857 ANI Pharmaceuticals shares in Q2 2025, an estimated $734K.
  • Schroder Investment Management Group first reported a position in ANI Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Schroder Investment Management Group's ANI Pharmaceuticals position peaked at $734K in Q1 2025.
  • 232 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2025.

Based on Schroder Investment Management Group's 13F filing for Q2 2025, filed 13 Aug 2025.